X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

Sumitomo Dainippon Pharma Announces Joint Research Agreement with MMV for Identification of Antimalarial Candidate Compounds

Content Team by Content Team
3rd May 2018
in Press Statements, Research & Development

Sumitomo Dainippon Pharma Co., Ltd. announced that it has signed an agreement with Medicines for Malaria Venture (Geneva, Switzerland; “MMV”) on joint research aimed at identifying antimalarial candidate compounds (“Joint Research”).

The Joint Research has its origins in the “Compound Screening Program for Malaria” (“Program”), which Sumitomo Dainippon Pharma and MMV have been jointly conducting since 2015. Using compounds (hit compounds) discovered from Sumitomo Dainippon Pharma’s compound library, the Joint Research aims to identify candidate compounds for antimalarials (lead compounds).

Both the Joint Research and the Program have been awarded funding from the Global Health Innovative Technology Fund (GHIT Fund).

Malaria is a parasitic disease most commonly transmitted by mosquitoes carrying Plasmodium parasites. According to the World Health Organization (WHO), the year 2016 saw over 200 million cases of malaria in 91 countries and regions mostly on the African continent, and the disease is estimated to have caused approximately 450,000 deaths, many of which were children aged five or younger*. With the onset of Plasmodium parasites that are resistant to existing therapies, innovative new drugs are eagerly anticipated to put a stop to this epidemic.

Under the framework of the Joint Research, Sumitomo Dainippon Pharma and MMV will commence detailed activity evaluation of multiple antimalarial candidate compounds with the aim of identifying those with properties that may lead to the development of new antimalarials within twelve months. MMV will utilize its expert knowledge and experience in the fight against malaria to promote research, while Sumitomo Dainippon Pharma will map out a drug discovery strategy from a scientific perspective based on its expertise and provide advice to MMV.

Through the Joint Research with MMV, Sumitomo Dainippon Pharma aims to explore the possibility of utilizing its innovative drug discovery technology to fight malaria, a disease with high unmet medical needs, and thus improve access to medicine

About Medicines for Malaria Venture (MMV)
MMV is a leading product development partnership (PDP) in the field of antimalarial research and development. Its mission is to contribute to treatment and prevention of malaria among vulnerable people in disease-endemic countries by discovering, developing, and delivering new, effective, and affordable antimalarial drugs. MMV manages one of the world’s largest portfolios of antimalarial R&D and access projects.

About GHIT Fund
The GHIT Fund launched in 2013 to leverage Japanese expertise and capacity for life-saving health innovations, including drugs, vaccines, and diagnostics, to combat HIV/AIDS, tuberculosis, malaria, neglected tropical diseases (NTDs) prevalent in the developing world. The GHIT Fund is the first international public-private partnership of its kind for global health research and development, between the Japanese Government: Ministry of Foreign Affairs, Ministry of Health, Labour and Welfare, private companies, the Bill & Melinda Gates Foundation, the Wellcome Trust, and United Nations Development Programme.

Previous Post

Baxter Reports First-Quarter 2018 Results and Increases Financial Outlook for Full-Year 2018

Next Post

DSM invests to increase global Dyneema® production capacity

Related Posts

News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
News

Report Indicates UK £62bn Behind In Global R&D Investment

3rd November 2022
News

Once More, M&As In Biotechechnology Industry Are Thriving

2nd November 2022
DNA
News

Ancient Viral DNA Guards Against Infections In Human Genome

31st October 2022
News

Omicron Subvariants Withstand Essential Antibody Treatments

31st October 2022
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Research And Development In UK Falls Behind Other Nations

28th October 2022
Next Post

DSM invests to increase global Dyneema® production capacity

Latest News

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In